Abstract
The article presents data of domestic and foreign authors illustrating current views of mechanisms underlying development, pathogenesis, and difficulties of differential diagnostics of coronary heart disease (CHD) concurrent with gastroesophageal reflux disease (GERD). High prevalence of both conditions and their common risk factors are responsible for frequent occurrence of co-morbidity. The available data suggest positive effect of treatment with proton pump inhibitors (decreased frequency of myocardial ischemia and heart arrhythmia). Co-morbidity of CHD and GERD requires long-term treatment and the use of safe medications having no adverse effects on the course of CHD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
